FindTrial
Sign In

Exploration of different treatment methods and curative effects after the first remission achieved by azacitidine combined with veneclax in the first treatment of acute myeloid leukemia in the elderly

Exploration of different treatment methods and curative effects after the first remission achieved by azacitidine combined with veneclax in the first treatment of acute myeloid leukemia in the elderly

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054281
Enrollment
Unknown
Registered
2021-12-12
Start date
2021-05-01
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia (AML)

Interventions

Microtransplant group 1 :Azacitidine+Venecla+Medium-dose Cytarabine+Microtransplantation
Microtransplant group 2:Azacitidine+Venecla+Microtransplantation
Control group:Azacitidine+Venecla

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Voluntarily participate in clinical research; I or my legal guardian fully understand and know this research and sign the informed consent; be willing to follow and be able to complete all experimental procedures; 2. Elderly AML patients (over 60 years old), all patients were diagnosed in accordance with the 2016 WHO diagnostic criteria for acute myeloid leukemia; 3. 1 or 2 courses of azacitidine combined with veneclax induction chemotherapy to achieve the first CR; 4. Physical performance status ECOG score <= 2 points.

Exclusion criteria

Exclusion criteria: 1. Have a history of other tumors; 2. Patients who did not achieve remission after 2 courses of azacitidine combined with veneclax; 3. Uncontrolled active infection; 4. HIV; 5. Active hepatitis can not be controlled within 2 x 10^3/ml after antiviral treatment.

Design outcomes

Primary

MeasureTime frame
Overall survival;Leukemia-free survival;Safety;Tolerance;—

Countries

China

Contacts

Public ContactOuyang Guifang
ouyangguifang2000@yahoo.com.cn+86 13967810405

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026